Methods of treating copper metabolism-associated diseases or disorders
AssigneeAlexion Pharmaceuticals, Inc.
InventorsPan Wei-Jian, Mark Ma, Brian Meltzer, Eugene Scott Swenson, Scott Edward Mosley, Ryan Pelto, Adam Quicquaro, Guillermo del Angel, Hareesh Chamarthi
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods of diagnosing and treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD).
Claims74
A method for treating a copper metabolism-associated disease or disorder in a subject, the method comprising:
- determining a concentration of total copper and a concentration of labile-bound copper (LBC) in the subject's biological sample;
- determining the ratio of LBC to total copper in the subject's biological sample;
- and
- administering to the subject a therapeutically effective amount of bis-choline tetrathiomolybdate when the ratio of LBC to total copper in the subject's biological sample is ≥ between 0.21 and 0.27.
A method of diagnosing a copper metabolism-associated disease or disorder in a subject, the method comprising:
- determining a concentration of total copper and a concentration of LBC in the subject's biological sample;
- determining the ratio of LBC to total copper in the subject's biological sample;
- and
- diagnosing the subject with a copper metabolism-associated disease or disorder if the ratio of LBC to total copper in the subject's biological sample is ≥ between 0.21 and 0.27.
A method of identifying a subject as suited for treatment with bis-choline tetrathiomolybdate, the method comprising:
- determining a concentration of total copper and a concentration of labile-bound copper (LBC) in the subject's biological sample;
- determining the ratio of LBC to total copper in the subject's biological sample;
- identifying the subject as suited for treatment with bis-choline tetrathiomolybdate when the ratio of LBC to total copper in the subject's biological sample is ≥ between 0.21 and 0.27, and
- optionally administering a therapeutically effective amount of bis-choline tetrathiomolybdate to the subject identified as suited for treatment with bis-choline tetrathiomolybdate.
A method for treating a copper metabolism-associated disease or disorder in a subject, the method comprising:
- determining a concentration of total copper and a concentration of directly measured non-ceruloplasmin-bound copper (dNCC) in the subject's biological sample;
- determining the ratio of dNCC to total copper in the subject's biological sample;
- and
- administering to the subject a therapeutically effective amount of bis-choline tetrathiomolybdate when the ratio of dNCC to total copper in the subject's biological sample is ≥ between 0.245 and 0.295.
A method of diagnosing a copper metabolism-associated disease or disorder in a subject, the method comprising:
- determining a concentration of total copper and a concentration of dNCC in the subject's biological sample;
- determining the ratio of dNCC to total copper in the subject's biological sample;
- and
- diagnosing the subject with a copper metabolism-associated disease or disorder if the ratio of dNCC to total copper in the subject's biological sample is ≥ between 0.245 and 0.295.
A method of identifying a subject as suited for treatment with bis-choline tetrathiomolybdate, the method comprising:
- determining a concentration of total copper and a concentration of dNCC in the subject's biological sample;
- determining the ratio of dNCC to total copper in the subject's biological sample;
- identifying the subject as suited for treatment with bis-choline tetrathiomolybdate when the ratio of dNCC to total copper in the subject's biological sample is ≥ between 0.245 and 0.295, and
- optionally administering a therapeutically effective amount of bis-choline tetrathiomolybdate to the subject identified as suited for treatment with bis-choline tetrathiomolybdate.
Dependencies are inferred from the claim text.